( MENAFN - News Direct) --News Direct-- By Jeremy Golden, Benzinga Clinical-stage biopharmaceutical company Candel Therapeutics, Inc. (NASDAQ: CADL) reported updated survival data from its randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer. Pancreatic cancer is the fourth leading cause of cancer-related death in the U.
S. The disease accounts for approximately 3% of all cancers, with an estimated 64,050 patients diagnosed in 2023. The randomized, controlled clinical trial is specifically looking into the safety and efficacy of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection – if possible – in borderline resectable pancreatic ductal adenocarcinoma (PDAC).
Very encouraging results were recently reported by the Needham, Massachusetts-based company. Patients reached an estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.
5 months in the control group in PDAC. At 24 months, the survival rate was 71.4% in CAN-2409 treated patients compared to only 16.
7% in the control group after chemoradiation. Thus, prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable PDAC. Importantly, 4 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with 2 patients surviving more than 50.
0 months from enrollment. Only 1 out of 6 patients in t.
